Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Hotgen Biotech Co., Ltd. (688068.SS)
Beijing, CN
Beijing Hotgen Biotech Co., Ltd. specializes in the complete process, from research and development to manufacturing and sales, of in-vitro diagnostic (IVD) solutions for medical and public safety purposes within the biomedical field. Their comprehensive range of products incorporates cutting-edge technologies like drug detection, CDC-compliant methods, up-conversion luminescence, colloidal gold, CLIA, sugar capture, microfluidics, and gene detection. These advanced diagnostic tools are designed to identify a broad spectrum of targets, including intestinal microorganisms, pathogens causing gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, various infectious diseases, Ebola virus antigens, biological warfare agents, other microorganisms, and mycotoxins. The company, founded in 2005, is headquartered in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.83% | +3.07% | -21.00% | -30.04% | -49.35% | -45.28% | -28.81% | +108.17% | -28.49% | +85.05% | +85.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-20.8% Q1'26: +24.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-8.2% Q1'26: -196.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-42.5% Q1'26: -65.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-68.2% Q1'26: -71.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-20.6% Q1'26: -23.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.7% ★ Q1'26: -1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.27× Q1'26: -0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
510.90M
est: 545.00M (-6.3%)
|
404.88M
est: 542.00M (-25.3%)
|
489.00M
489.00M – 489.00M
-9.8% YoY
|
592.00M
592.00M – 592.00M
+21.1% YoY
|
718.00M
718.00M – 718.00M
+21.3% YoY
|
| EBITDA |
-102.98M
est: 31.90M (-422.8%)
|
-189.01M
est: 31.73M (-695.7%)
|
28.63M
28.63M – 28.63M
-9.8% YoY
|
34.66M
34.66M – 34.66M
+21.1% YoY
|
42.03M
42.03M – 42.03M
+21.3% YoY
|
| EBIT |
-187.32M
est: -25.58M (-632.2%)
|
-275.98M
est: -25.44M (-984.7%)
|
-22.96M
-22.96M – -22.96M
+9.8% YoY
|
-27.79M
-27.79M – -27.79M
-21.1% YoY
|
-33.71M
-33.71M – -33.71M
-21.3% YoY
|
| Net Income |
-191.00M
|
-210.52M
est: -124.05M (-69.7%)
|
-59.21M
-59.21M – -59.21M
+52.3% YoY
|
7.52M
7.52M – 7.52M
+112.7% YoY
|
67.67M
67.67M – 67.67M
+800.0% YoY
|
| SGA |
289.77M
est: 171.44M (+69.0%)
|
130.50M
est: 170.49M (-23.5%)
|
153.82M
153.82M – 153.82M
-9.8% YoY
|
186.22M
186.22M – 186.22M
+21.1% YoY
|
225.85M
225.85M – 225.85M
+21.3% YoY
|
| EPS |
-2.07
|
-2.24
est: -1.32 (-69.7%)
|
-0.63
-0.63 – -0.63
+52.3% YoY
|
0.08
0.08 – 0.08
+112.7% YoY
|
0.72
0.72 – 0.72
+800.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 113.0K | 0.29% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 32.5K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Changqing Lin | Chairman & GM | — | male |
| Lida Xu | Chairman of the Supervisory Board & R&D Director Bioinformatics Center | — | female |
| Xiaochi Jie | Deputy General Manager | — | male |
| Yanzhao Li | Deputy GM & Director | — | male |
| Yongzhan Shi | Deputy GM, Secretary & Director | — | male |
| Zhongchao Jie | Financial Director & Accounting Supervisor | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688068.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
